Company profile
Lomond Therapeutics Holdings, Inc.
Privately held: no public share price (An SEC-reporting company (10-K/10-Q filer) after a Nov 2024 reverse merger into a SPAC shell, but with no Section 12(b) exchange registration and no trading symbol — SEC-reporting is not the same as exchange-traded, and no traded equity currently exists. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.streetinsider.com/SEC+Filings/Form+DA+Lomond+Therapeutics+Hold/24324603.html]) · United States
Assets
(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BCL-2Small molecule | Acute Myeloid Leukemia | |
| Phase 1 | BCL-2 | Acute Myeloid Leukemia |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.